GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (NAS:VIVS) » Definitions » Operating Margin %

VIVS (VivoSim Labs) Operating Margin % : -6,184.31% (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is VivoSim Labs Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. VivoSim Labs's Operating Income for the three months ended in Mar. 2025 was $-3.15 Mil. VivoSim Labs's Revenue for the three months ended in Mar. 2025 was $0.05 Mil. Therefore, VivoSim Labs's Operating Margin % for the quarter that ended in Mar. 2025 was -6,184.31%.

The historical rank and industry rank for VivoSim Labs's Operating Margin % or its related term are showing as below:

VIVS' s Operating Margin % Range Over the Past 10 Years
Min: -13840.37   Med: -977.91   Max: -765.27
Current: -8761.11


VIVS's Operating Margin % is ranked worse than
91.86% of 983 companies
in the Biotechnology industry
Industry Median: -115.49 vs VIVS: -8761.11

VivoSim Labs's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

VivoSim Labs's Operating Income for the three months ended in Mar. 2025 was $-3.15 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-12.62 Mil.


VivoSim Labs Operating Margin % Historical Data

The historical data trend for VivoSim Labs's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VivoSim Labs Operating Margin % Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -765.27 -4,792.16 -13,840.37 -8,761.11

VivoSim Labs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,675.86 -8,682.05 -8,693.33 -14,450.00 -6,184.31

Competitive Comparison of VivoSim Labs's Operating Margin %

For the Biotechnology subindustry, VivoSim Labs's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Operating Margin % distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Operating Margin % falls into.


;
;

VivoSim Labs Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

VivoSim Labs's Operating Margin % for the fiscal year that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (A: Mar. 2025 ) / Revenue (A: Mar. 2025 )
=-12.616 / 0.144
=-8,761.11 %

VivoSim Labs's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-3.154 / 0.051
=-6,184.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VivoSim Labs  (NAS:VIVS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


VivoSim Labs Operating Margin % Related Terms

Thank you for viewing the detailed overview of VivoSim Labs's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


VivoSim Labs Business Description

Traded in Other Exchanges
N/A
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075